Literature DB >> 1890625

Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys.

J Bergman1, B K Madras, R D Spealman.   

Abstract

The behavioral effects of dopamine antagonists differing in affinity and selectivity at D1 and D2 dopamine receptors were compared in squirrel monkeys responding under a fixed-interval schedule of stimulus-shock termination. D1-selective antagonists included (R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7 -ol, SCH 23390; its enantiomer (S)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7 -ol, SCH 23388; [(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H - benzo(d)naphtho-(2,1-b)azepine], SCH 39166; (R)-7-bromo-8-hydroxyl-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine, R-SKF 83566; (R)-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol, R-SKF 83692; 2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol, RS-SKF 83692. D2-selective antagonists included cis-N-(1-benzyl-2-methylpyrrolidine-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide, YM-09151-2, eticlopride, raclopride, haloperidol, risperidone, remoxipride, S-sulpiride and R-sulpiride; nonselective dopamine antagonists were S-butaclamol and chlorpromazine. Regardless of selectivity for D1 or D2 receptors, all drugs produced dose-related decreases in fixed-interval responding. A high degree of stereoselectivity was evident for both D1 antagonists (SCH 23390 and R-SKF 83692 more potent than, respectively, SCH 23388 and RS-SKF 83692) and D2 antagonists (S-sulpiride more potent than R-sulpiride). High doses of the D1 and D2 antagonists also reduced motor activity and impaired coordination in monkeys in the home cage after test sessions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890625

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.

Authors:  Rajeev I Desai; John L Neumeyer; Carol A Paronis; Phong Nguyen; Jack Bergman
Journal:  Eur J Pharmacol       Date:  2006-12-01       Impact factor: 4.432

2.  Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish.

Authors:  T D Irons; P E Kelly; D L Hunter; R C Macphail; S Padilla
Journal:  Pharmacol Biochem Behav       Date:  2012-12-28       Impact factor: 3.533

3.  Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.

Authors:  S Rosenzweig-Lipson; P Hesterberg; J Bergman
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

4.  Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Authors:  Donna M Platt; Joshua S Rodefer; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

5.  Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice.

Authors:  C Savio Chan; Jayms D Peterson; Tracy S Gertler; Kelly E Glajch; Ruth E Quintana; Qiaoling Cui; Luke E Sebel; Joshua L Plotkin; Weixing Shen; Myriam Heiman; Nathaniel Heintz; Paul Greengard; D James Surmeier
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

6.  The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity.

Authors:  H J Rijnders; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys.

Authors:  Stefani N Von Huben; Sophia A Davis; Christopher C Lay; Simon N Katner; Rebecca D Crean; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

Review 8.  Survey on the pharmacodynamics of the new antipsychotic risperidone.

Authors:  A A Megens; F H Awouters; A Schotte; T F Meert; C Dugovic; C J Niemegeers; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 9.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

10.  Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.

Authors:  Alexandra Hamacher; Mathias Weigt; Michael Wiese; Barbara Hoefgen; Jochen Lehmann; Matthias U Kassack
Journal:  BMC Pharmacol       Date:  2006-09-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.